- Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus in a clinically relevant animal model of surgical site infections
- The vaccine antigens significantly protected large, non-rodent animals against surgical site infections, indicating promising potential for clinical efficacy in human trials
Birgitte Rønø, Chief Scientific Officer at Evaxion, expresses enthusiasm: “We are very thrilled about the encouraging data and believe that our EVX-B1 vaccine antigens hold the potential for efficacy in human trials – a milestone that previous vaccine attempts have failed to achieve.”
There is no S. aureus vaccine available for human use. This pathogen can cause infections of multiple organs and tissues, which can be profoundly severe or even fatal. Most at risk are individuals with chronic conditions and patients undergoing surgeries. Also, the presence of antibiotic-resistant S. aureus is limiting available treatment options. The
Three separate studies in large, non-rodent animals were conducted with the following conclusions:
- The EVX-B1 vaccine antigens significantly reduced S. aureus bacterial burden in a surgical site infection model
- Induction of meaningful antigen-specific antibody titers in all vaccinated animals
- The ability of the antigens to induce a protective immune response in the animals when being colonized with S. aureus mimicking the human situation
- Ability of the immune blood to neutralize clinically relevant S. aureus in a whole blood killing assay, holding promise for translational assay readout in early clinical development
About EVX-B1
The EVX-B1 antigens have been designed using Evaxion’s AI-Immunology™ platform. AI-Immunology™ has enabled the identification of novel Staphylococcus aureus antigens, paving the way for developing a vaccine with the potential for broad protection against clinically relevant S. aureus strains.
About Staphylococcusaureus
According to the
About EVAXION
Forward-Looking Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from the worldwide ongoing COVID-19 pandemic and the ongoing conflict in the region surrounding
© OMX, source